29/05/2024

Top Business

Trend About Business

Roche’s Ocrevus’ 10-year data shows MS drug cuts disability progression

Roche’s Ocrevus’ 10-year data shows MS drug cuts disability progression

Roche’s Ocrevus’ 10-year data shows MS drug cuts disability progression

Md Saiful Islam Khan

Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) multiple sclerosis (MS) drug Ocrevus showed that after 10 years of treatment 77% of patients with relapsing MS were free from disability progression and 92% continued to walk without help.

The Swiss pharma giant reported 10 years of